

**IN THE CLAIMS**

1-10. (Cancelled)

11. (Currently Amended) ~~An apparatus for administering an active agent to a subject, A~~  
punctal plug comprising:

a plug body, including a porous or absorbent material, the plug body sized and shaped for at least partial insertion into a lacrimal punctum and extending from a proximal end portion to a distal end portion; and

an active agent disposed substantially throughout an exterior surface of the plug body from approximately the proximal end portion to approximately the distal end portion, the active agent configured to provide a sustained release to tissue at or near one or both of [[the]] an eye or a nasolacrimal system of [[the]] a subject.

12. (Currently Amended) ~~An apparatus according to~~ The punctal plug of claim 11, wherein the ocular implant is a punctal plug active agent is disposed substantially throughout the plug body from approximately the proximal end portion to approximately the distal end portion.

13. (Currently Amended - Withdrawn) ~~An apparatus according to~~ The punctal plug of claim 11, wherein the ocular implant is a punctal plug, the active agent being on distal end portion of the plug body includes a stem, the stem configured to insert of the plug for insertion into a canaliculus of the subject and including an exposed medication-discharging supply of the active agent at one or more external surfaces thereof.

14. (Currently Amended) ~~An apparatus according to~~ The punctal plug of claim 11, wherein the ocular implant is a punctal plug; proximal end portion of the plug body includes an outer stopper structure extending at least partially from or around an outer body surface and configured to seat against the lacrimal punctum, the outer stopper structure including an exposed medication-discharging supply of the active agent being on a stopper of the plug, the plug having

~~a stem for insertion into a punctal aperture of the subject at one or more external surfaces thereof.~~

15. (Currently Amended) ~~An apparatus according to~~ The punctal plug of claim 11, wherein the active agent ~~[[is]]~~ includes a medicine.

16. (Currently Amended - Withdrawn) ~~An apparatus according to~~ The punctal plug of claim ~~[[11]]~~ 15, wherein the active agent ~~[[is]]~~ includes a medicine selected from the group comprising: topical prostaglandin; latanoprost; travaprost; bimatoprost; a medication for a treatment for corneal infections; ciprofloxacin; moxifloxacin; gatifloxacin; a systemic medication; a medication for treating hypertension; atenolol; nifedipine; and hydrochlorothiazide.

17. (Currently Amended) ~~An apparatus according to~~ The punctal plug of claim 11, wherein the active agent ~~[[is]]~~ includes a medication for the topical treatment of glaucoma ~~or corneal infection.~~

18. (Currently Amended - Withdrawn) ~~An apparatus according to~~ The punctal plug of claim 11, wherein ~~the implant is hollow~~ the plug body includes a lumen extending from the proximal end portion to the distal end portion, the lumen configured for a passing-tears passage of tear fluid therethrough.

19. (Currently Amended - Withdrawn) ~~An apparatus according to~~ The punctal plug of claim ~~[[11]]~~ 18, wherein ~~the implant is hollow for passing tears and the active~~ comprising an exposed medication-discharging supply of the active agent is made available at an interior of the hollow implant disposed on at least one portion of the lumen wall, the active agent configured to treat the nasolacrimal system.

20. (New) The punctal plug of claim 11, wherein the entire plug body is saturated with the active agent.

21. (New) The punctal plug of claim 11, comprising an exposed medication-discharging supply of the active agent disposed on at least one external surface of the proximal end portion of the plug body, the active agent configured to treat the eye.
22. (New) The punctal plug of claim 21, wherein the exposed medication-discharging supply of the active agent is configured to provide the sustained release to tissue at or near the eye for a time period of at least about 3 months after implant.
23. (New) The punctal plug of claim 21, wherein the exposed medication-discharging supply of the active agent includes one or more agent-discharging bands.
24. (New - Withdrawn) The punctal plug of claim 11, comprising an exposed medication-discharging supply of the active agent disposed on at least one external surface of the distal end portion, the active agent configured to treat, at least in part, the nasolacrimal system.
25. (New - Withdrawn) The punctal plug of claim 24, wherein the exposed medication-discharging supply of the active agent includes one or more agent-discharging bands.
26. (New) The punctal plug of claim 11, comprising an exposed medication-discharging supply of the active agent disposed on all external surfaces of the plug body.
27. (New) The punctal plug of claim 11, wherein the distal end portion of the plug body includes an inner stopper structure, the inner stopper structure configured to at least partially secure an implant location of the plug body.
28. (New - Withdrawn) The punctal plug of claim 13, wherein the exposed medication-discharging supply of the active agent is configured to provide the sustained release to tissue of the canaliculus wall.

29. (New) The punctal plug of claim 14, wherein the outer stopper structure is configured to completely seal the lacrimal punctum against a flow of tear fluid therethrough.
30. (New) A punctal plug comprising:  
a plug body, sized and shaped for at least partial insertion into a lacrimal punctum; and  
an exposed medication-discharging supply of an active agent at least partially disposed on at least one external surface of the plug body, the exposed medication-discharging supply configured to provide a sustained release of the active agent to one or both of an eye or a nasolacrimal system for a time period of at least about 3 months after implant..
31. (New) The punctal plug of claim 30, wherein the exposed medication-discharging supply of the agent is disposed on at least one surface of a proximal end portion of the plug body, the active agent configured to treat the eye.
32. (New - Withdrawn) The punctal plug of claim 30, wherein the exposed medication-discharging supply of the agent is disposed on at least one surface of a distal end portion of the plug body, the active agent configured to treat the nasolacrimal system.
33. (New) The punctal plug of claim 30, wherein a distal end portion of the plug body includes an inner stopper structure configured to at least partially secure an implant location of the plug body.
34. (New) The punctal plug of claim 30, wherein the entire plug body is substantially saturated with the active agent.
35. (New) The punctal plug of claim 34, wherein the exposed medication-discharging supply of the agent is disposed on all external surfaces of the plug body.

36. (New - Withdrawn) The punctal plug of claim 30, wherein the active agent includes a medicine selected from the group comprising: topical prostaglandin; latanoprost; travaprost; bimataprost; a medication for a treatment for corneal infections; ciprofloxacin; moxifloxacin; gatifloxacin; a systemic medication; a medication for treating hypertension; atenolol; nifedipine; and hydrochlorothiazide.

---